- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price live, this page displays HK 1349 stock exchange data. View the 1349 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd real time stock price chart below.
What Is the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Price Today?
The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price today is 3.85.
What Is the Stock Symbol for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd?
The stock symbol for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is ""1349.""
What Stock Exchange Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Trade On?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1349 quote. (ISIN: CNE1000000W4)
What Is the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Price Today?
The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd stock price today is 3.85.
What Is the Stock Symbol for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd?
The stock symbol for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is ""1349.""
What Stock Exchange Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Trade On?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is listed and trades on the Hong Kong stock exchange.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd a Good Stock to Buy?
Determining whether Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1349 quote. (ISIN: CNE1000000W4)
3.85
+0.03(+0.79%)
Closed·
Fair Value
An estimate of a Shanghai Fudan-Zhangjiang Bio-Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.80
3.86
52 wk Range
1.70
5.29
1349 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1349 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Shanghai Fudan-Zhangjiang Bio-Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.803.86
52 wk Range
1.705.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1349 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Shanghai Fudan-Zhangjiang Bio-Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Profile
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases. Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. Additionally, the company engages in the technology development, transfer, consulting, and promotion activities. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. was founded in 1996 and is based in Shanghai, the People's Republic of China.
Compare 1349 to Peers and Sector
Metrics to compare | 1349 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1349PeersSector | |
|---|---|---|---|---|
P/E Ratio | −330.3x | 31.3x | −0.6x | |
PEG Ratio | 2.72 | −0.49 | 0.00 | |
Price/Book | 3.6x | 3.1x | 2.6x | |
Price / LTM Sales | 12.0x | 3.6x | 3.3x | |
Upside (Analyst Target) | - | 0.9% | 40.0% | |
Fair Value Upside | Unlock | 12.4% | 4.7% | Unlock |
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-- / --
Revenue / Forecast
210.18M / --
FAQ
What Stock Exchange Does Shanghai Fudan-Zhangjiang Bio-Pharma Trade On?
Shanghai Fudan-Zhangjiang Bio-Pharma is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for Shanghai Fudan-Zhangjiang Bio-Pharma?
The stock symbol for Shanghai Fudan-Zhangjiang Bio-Pharma is "1349."
What Is the Shanghai Fudan-Zhangjiang Bio-Pharma Market Cap?
As of today, Shanghai Fudan-Zhangjiang Bio-Pharma market cap is 9.41B.
What Is Shanghai Fudan-Zhangjiang Bio-Pharma's Earnings Per Share (TTM)?
The Shanghai Fudan-Zhangjiang Bio-Pharma EPS (TTM) is -0.02.
When Is the Next Shanghai Fudan-Zhangjiang Bio-Pharma Earnings Date?
Shanghai Fudan-Zhangjiang Bio-Pharma will release its next earnings report on 22 Oct 2025.
From a Technical Analysis Perspective, Is 1349 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Shanghai Fudan-Zhangjiang Bio-Pharma Stock Split?
Shanghai Fudan-Zhangjiang Bio-Pharma has split 0 times.
How Many Employees Does Shanghai Fudan-Zhangjiang Bio-Pharma Have?
Shanghai Fudan-Zhangjiang Bio-Pharma has 899 employees.
What is the current trading status of Shanghai Fudan-Zhangjiang Bio-Pharma (1349)?
As of 22 Aug 2025, Shanghai Fudan-Zhangjiang Bio-Pharma (1349) is trading at a price of 3.85, with a previous close of 3.82. The stock has fluctuated within a day range of 3.80 to 3.86, while its 52-week range spans from 1.70 to 5.29.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.